Biotechnology Analyst Kluska, along with Dr. Kim, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discuss Celldex’s New Barzovolimab Data in CSU and PN on an Analyst/Industry conference call to be held on November 6 at 3 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLDX:
- Celldex price target raised to $80 from $73 at H.C. Wainwright
- Celldex’s barzolvolimab meets primary endpoint in Phase 2 urticaria study
- Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
- Celldex files automatic mixed securities shelf